Head and Neck Squamous Cell Carcinoma Clinical Trials in Hanover

7 recruitingHanover, Germany

Showing 17 of 7 trials

Recruiting
Phase 3

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients

Head and Neck Squamous Cell Carcinoma
Merus B.V.500 enrolled207 locationsNCT06496178
Recruiting
Phase 3

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca1,145 enrolled305 locationsNCT06129864
Recruiting
Phase 3

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Locally Advanced Head and Neck Squamous Cell CarcinomaAged
Johnson & Johnson Enterprise Innovation Inc.500 enrolled189 locationsNCT04892173
Recruiting
Phase 3

Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC

Recurrent Head and Neck Squamous Cell Carcinoma
Universität des Saarlandes214 enrolled18 locationsNCT07026474
Recruiting
Phase 3

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Head and Neck Squamous Cell Carcinoma
Merus B.V.500 enrolled185 locationsNCT06525220
Recruiting
Phase 2Phase 3

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

Unresectable Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck CancerRecurrent Head and Neck Cancer
BioNTech SE350 enrolled189 locationsNCT04534205
Recruiting
Phase 1Phase 2

Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell CarcinomaFanconi Anemia
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau25 enrolled2 locationsNCT06648096